Related Experiment Video
Updated: May 14, 2026

Visualization and Quantification of TGFβ/BMP/SMAD Signaling under Different Fluid Shear Stress Conditions using Proximity-Ligation-Assay
Published on: September 14, 2021
The transforming growth factor-Beta signaling pathway involvement in cardiovascular lesions in
1Genetics Division, Department of Pediatrics, LAC + USC Medical Center, University of Southern California, General Laboratory Building Rm 1 G-24, 1801 Marengo Street, Los Angeles, 90033, CA, USA, syano@usc.edu.
Abstract:
Mucopolysaccharidoses (MPS) are a group of genetic disorders due to deficiency of lysosomal enzymes resulting in impaired glycosaminoglycan metabolism. All types of MPS can present with cardiovascular manifestation, although MPS-I, II, and VI seem to have more severe involvement than the other types. Enzyme replacement therapy (ERT) is available for MPS-I, II, and VI. Cardiovascular changes including hypertrophic cardiomyopathy, thickened valvular lesions, and coronary artery lesions often poorly respond to ERT and are well known as leading causes of death in patients with MPS-I. The mechanisms to cause these changes in MPS-I have not been well characterized. Immunohistopathological studies were conducted on the cardiac specimens from a patient with MPS-I who died due to sudden cardiac failure. Phosphorylated Smad2 staining showed hyperactive transforming growth factor-beta (TGF-β) signals in the intimal layer with myointimal proliferation causing stenosis in the coronary arteries as well as in the thickened endocardium and in the myocardial cells. TGF-β is involved in the pathogenesis of cardiovascular diseases including hypertrophic cardiomyopathy and vascular atherosclerosis. The primary mechanisms to cause hyperactive TGF-β signals in MPS-I are unknown. The similar mechanisms leading to hyperactive TGF-β signals may exist in the other types of MPS. The findings of TGF-β hyperactivity in the cardiovascular lesions in a patient with MPS-I may lead to a new therapeutic approach. Further studies are warranted to evaluate the effectiveness of the medications that suppress TGF-β signals, such as losartan, in preventing or improving cardiaovascular lesions in patients with MPS.
Insights
Mucopolysaccharidoses (MPS) cause cardiovascular issues due to enzyme deficiencies. In MPS-I, hyperactive transforming growth factor-beta (TGF-β) signals contribute to heart and blood vessel damage, suggesting new therapeutic targets.
Area of Science:
- Genetics and Molecular Biology
- Cardiovascular Medicine
- Lysosomal Storage Diseases
Background:
- Mucopolysaccharidoses (MPS) are genetic disorders impairing glycosaminoglycan metabolism.
- Cardiovascular manifestations are common in MPS, particularly MPS-I, II, and VI.
- Existing enzyme replacement therapy (ERT) has limited efficacy for cardiovascular complications in MPS-I.
Purpose of the Study:
- To investigate the underlying mechanisms of cardiovascular pathology in Mucopolysaccharidosis type I (MPS-I).
- To explore the role of transforming growth factor-beta (TGF-β) signaling in MPS-I cardiovascular disease.
- To identify potential new therapeutic strategies for MPS-associated cardiac conditions.
Main Methods:
- Immunohistopathological analysis of cardiac tissue from an MPS-I patient.
- Assessment of phosphorylated Smad2 staining to evaluate TGF-β signaling activity.
- Correlation of TGF-β pathway activation with observed cardiovascular lesions.
Main Results:
- Hyperactive TGF-β signaling was identified in the intimal layer, endocardium, and myocardial cells.
- Evidence of myointimal proliferation and coronary artery stenosis linked to TGF-β hyperactivity.
- Cardiovascular lesions, including hypertrophic cardiomyopathy and thickened valves, showed signs of TGF-β pathway involvement.
Conclusions:
- Hyperactive TGF-β signaling is implicated in the pathogenesis of cardiovascular lesions in MPS-I.
- These findings suggest TGF-β pathway modulation as a potential therapeutic avenue for MPS-I cardiovascular disease.
- Further research is needed to explore TGF-β inhibitors, like losartan, for treating MPS-related cardiovascular complications.
Related Concept Videos
TGF - β Signaling Pathway
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Proteoglycans
Regulation of Angiogenesis and Blood Supply
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Hedgehog Signaling Pathway

